The ADDF accelerates the discovery of drugs to prevent and treat Alzheimer's disease through research funding and portfolio management.
The Alzheimer's Drug Discovery Foundation (ADDF) is dedicated to advancing the discovery of drugs to prevent and treat Alzheimer's disease. ADDF funds research programs focused on drug development, biomarkers, and prevention strategies. In 2024, ADDF catalyzed significant breakthroughs, including major investments in scalable blood tests and the cataloging of Alzheimer's biomarkers. The foundation also marked the 10th anniversary of the Goodes Prize and celebrated the FDA approval of Kisunla (Donanemab). ADDF's diverse portfolio is one of the largest worldwide, emphasizing lifestyle interventions and innovative diagnostics.
UCL's Department of Psychology and Language Sciences is dedicated to advancing understanding of human behavior, cognition, and language through innovative research and teaching.
Founded in 1969, the Society for Neuroscience (SfN) now has nearly 35,000 members in more than 95 countries. Year-round programming includes the publishing of two highly regarded scientific journals, JNeurosci and eNeuro; professional development resources and career training through Neuronline, the Society’s home for learning and discussion; science advocacy and public policy engagement including annual Capitol Hill Day; and a variety of engaging public outreach efforts, led by the expanding and interactive collection of public-facing resources on BrainFacts.org.
The Department of Psychological and Brain Sciences at Texas A&M University produces scientific discoveries that illuminate psychological processes in human behavior, focusing on mental and physical health disorders, and the psychological and social processes that influence thoughts, feelings, and behaviors. The department is highly research-active, with faculty leading the field in editorial boards and grant review panels, and preparing students for leadership roles in their fields.